公开(公告)号：US20160152712A1

公开(公告)日：2016-06-02

申请号：US14956585

申请日：2015-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef YARDEN ,  Maicol Mancini ,  Nadège Gaborit

IPC: C07K16/28 ,  A61K31/517 ,  A61N5/10 ,  C07K16/40 ,  A61K39/395 ,  C07K16/30 ,  A61K31/506

CPC classification number: C07K16/2863 ,  A61K31/506 ,  A61K31/517 ,  A61K39/39558 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.

Abstract translation: 提供了治疗具有对酪氨酸激酶抑制剂（TKI）具有抗性的癌症患者的方法。 因此，提供了一种方法，其包括向受试者施用治疗有效量的抗体，其包含抗EGFR抗体，抗HER2抗体和抗HER3抗体。 还提供了用于治疗对TKI的耐癌性的组合物和制品。 还提供了治疗非耐药性肿瘤的方法。

公开(公告)号：US10526416B2

公开(公告)日：2020-01-07

申请号：US15508112

申请日：2015-09-08

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Nadège Gaborit ,  Moshit Lindzen

IPC: C07K16/00 ,  A61K39/395 ,  C07K16/32 ,  A61K47/68 ,  C07K16/30 ,  G01N33/574 ,  A61K39/00 ,  C07K16/28

Abstract: An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a KD value of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a KD value of 10 nM or lower.

公开(公告)号：US10011659B2

公开(公告)日：2018-07-03

申请号：US14956585

申请日：2015-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Yosef Yarden ,  Maicol Mancini ,  Nadège Gaborit

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  A61K31/506 ,  A61K31/517 ,  A61K39/395 ,  A61N5/10 ,  C07K16/40 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61K31/506 ,  A61K31/517 ,  A61K39/39558 ,  A61K2039/507 ,  A61N5/10 ,  C07K16/30 ,  C07K16/3023 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76

Abstract: Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.